Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genenta Science S.p.A. - American Depositary Shares (NQ:GNTA)

2.042 -0.158 (-7.19%)
Streaming Delayed Price Updated: 10:26 AM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genenta Science S.p.A. - American Depositary Shares

< Previous 1 2 Next >
News headline image
Sphere 3D Corp. (NASDAQ: ANY) Surges on Acquisition AI Infrastructure Platform Acquisition – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Genenta signs Definitive Agreements with Sophia High Tech
Genenta enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Focused on selective acquisitions of high-quality companies in strategic industrial sectors 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Science Provides Update on CEO Ownership
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Synergy (NASDAQ: SNYR) CEO Jack Ross at NASDAQ Discusses FOCUSfactor® Beverage Production, Rollout, and Expansion – Watch Now! – More Stocks Inside
Via AB Newswire
News headline image
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Myseum (NASDAQ: MYSE) CEO Darin Myman Highlights Privacy-Driven Future of Social Media – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Genitourinary Tumor Study Ongoing with Active Screening and Enrollment 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
Anemocyte established Cell Banks and Plasmids for Viral Vector Production 
From GENENTA SCIENCE SPA; Anemocyte
Via GlobeNewswire
News headline image
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in San Francisco 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta Science (NASDAQ: GNTA) Featured in Coverage of the 36th Annual Roth Conference
Via Investor Brand Network
News headline image
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta to Present at Upcoming Scientific and Investor Conferences
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta to Provide Update on Lead Product Temferon™
Prof. Luigi Naldini will present updates on the efficacy of Temferon in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients 
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta Science (NASDAQ: GNTA) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
Genenta Sciences (NASDAQ: GNTA) Featured in Virtual Coverage of Roth’s Healthcare Opportunities Conference
Via Investor Brand Network
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.